

Mark Gaze is a consultant clinical oncologist, with expertise in paediatric and molecular radiotherapy, at University College London Hospitals and Great Ormond Street Hospital for Children, and Honorary Associate Professor at University College London. His interest in neuroblastoma research started with his MD thesis, entitled *The Targeted Radiotherapy of Neuroblastoma*. He has chaired the NCRI Children's Group's Neuroblastoma Committee, and the CCLG, as well as the SIOPEN Radiotherapy Committee. He is a member of both SIOP-Europe's QUARTET and Radiation Oncology Working Group's Steering Groups, and a member of the PROS Executive. He is the Chief- or Co-Investigator of several neuroblastoma trials including MINIVAN, LuDO and IMAT-Neuroblastoma, and part of the management teams of SIOPEN's VERITAS and High-Risk 2 trials. Although principally a clinician, he collaborates with a number of basic science groups working on neuroblastoma biology. He has an extensive, neuroblastoma-focused, publication record.

